Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 4/21/2016 |
| Start Date: | May 2013 |
| End Date: | January 2016 |
Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13,
an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness
on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.
an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness
on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.
In a single blind randomized parallel group design, we will evaluate the whether a single
dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning,
declarative memory, and working memory, and associated task-related increases in BOLD
activation in hippocampus and dorsolateral prefrontal cortex, respectively. Positive
findings will provide biomarker evidence for GLYX-13 effects on neural systems underlying
these cognitive processes.
dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning,
declarative memory, and working memory, and associated task-related increases in BOLD
activation in hippocampus and dorsolateral prefrontal cortex, respectively. Positive
findings will provide biomarker evidence for GLYX-13 effects on neural systems underlying
these cognitive processes.
Inclusion Criteria:
For all Individuals
- Male and female subjects
- Ages 18 - 40 years
- General intellectual abilities falling broadly within the average range (estimated IQ
between 80 - 119)
- Sufficient ability to understand study requirements and provide written informed
consent
For Patients
-Diagnosis of Schizophrenia or Schizoaffective Disorder
Exclusion Criteria:
For all individuals:
- History of neurologic disorder or systemic medical condition that may interfere with
central nervous system function
- History of seizures
- History of heard injury with loss of consciousness or concussion
- Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid, or
other agent that is being abused in the opinion of the investigator
- Females who are currently pregnant or plan to become pregnant during the study period
- History of allergy, sensitivity, or intolerance to N-methyl-D-Aspartate receptor
(NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone,
dextropropoxyphene, or ketobemidone
- History of any ferromagnetic object in the body
- Presence of any medical device or implant for which MRI is contraindicated including
cardiac pacemaker, aneurysm clip, cochlear implant, copper intrauterine device (IUD),
neurostimulator, or any other device deemed unsafe
- Bullet or shrapnel in body
- Metallic braces or permanent retainer
- Significant claustrophobia
For Healthy Individuals
- Personal history of any Axis I disorder according to SCID criteria
- History of treatment with antidepressant, antipsychotic, stimulant,sedative/
hypnotic, mood stabilizing, or anticholinergic medications or lithium
- History among first-degree family members of any psychotic illness or major mood
disorder (e.g., major depressive disorder, recurrent; bipolar I or II disorder)
For Patients
- Treatment with Clozaril
- Change in medication within 1 month
- Hospitalization within 1 month
We found this trial at
1
site
Click here to add this to my saved trials
